Hostname: page-component-7bb8b95d7b-pwrkn Total loading time: 0 Render date: 2024-09-26T07:11:47.225Z Has data issue: false hasContentIssue false
  • English
  • Français

Prostaglandins in congenital heart disease—potential for confusion

Published online by Cambridge University Press:  19 August 2008

R. John Madar ,
Tim J.D. Donaldson  and
Stewart Hunter
R. John Madar*
Affiliation:
Departments of Pharmacy, Freeman Hospital, Newcastle-upon-Tyne
Tim J.D. Donaldson
Affiliation:
Departments of Pharmacy, Freeman Hospital, Newcastle-upon-Tyne
Stewart Hunter
Affiliation:
Departments of and Paediatric Cardiology, Freeman Hospital, Newcastle-upon-Tyne
*
Dr. R. J. Madar, Dept of Paediatric Cardiology, Freeman Hospital, High Heaton, Newcastle-upon-Tyne NE7 7DN, UK. Tel. 44-91 284 3111; Fax. 44-91 213 2167.
Get access Rights & Permissions [Opens in a new window]

Extract

the use of prostaglandians in maintaining the patency of the arterial duct in congenital heart disease is well established. Intravenous1-3 and ora12–4 administration has been used, although for acute use intravenous and possibly intraosseous5 routes are favored. Both prostaglandin E1 (alprostadil—ProstinVR: Upjohn)1,4 and prostaglandin E2 (dinoprostone—Prostin E2: Upjohn)2,3 are used for this purpose, although only prostaglandin E1 is licensed for this indication in the United Kingdom. Prostaglandin E1 costs approximately 8 times more than prostaglandin E2 (£56.96 versus £7.43 per vial).

Type
Experience and Comment
Information
Cardiology in the Young , Volume 5 , Issue 2 , April 1995 , pp. 202 - 203
Copyright
Copyright © Cambridge University Press 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Hallidie-Smith, KA.. Prostaglandin E1 in suspected ductusdependent cardiac malformation. Arch Dis Child 1984; 59: 1020–1026.CrossRefGoogle Scholar
Silove, ED, Roberts, DGV, DeGiovanni, JV.Evaluation of oral and low-dose intravenous prostaglandin E2 in management of ductus-dependent congenital heart disease. Arch Dis Child 1985; 60: 1025–1030.CrossRefGoogle ScholarPubMed
Thanopoulos, BD, Andreou, A, Frimas, C.Prostaglandin E2 administration in infants with ductus dependent cyanotic congenital heart disease. Eur J Pediatr 1987; 146: 279–282.CrossRefGoogle ScholarPubMed
Matsuura, H, Saji, T, Yamamoto, S, Ishikita, T, Aoki, Y, Matsuo, N.Dilation of the ductus arteriosus by oral prosragland in E1derivative in cyanotic congenital heart diseases. Am Heart J 1993; 125: 1453–1454.CrossRefGoogle Scholar
Ryder, IG, Munro, HM, Doull, IJM.Intraosseous infusion for resuscitation. Archives Dis Child 1991; 66: 1442–1443.CrossRefGoogle ScholarPubMed